Novo Nordisk CEO says experimental weight loss pill could become a best-in-class drug

Lars Fruergaard Jørgensen’s remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin.

Previous post Rats, bedbugs and freezing cold: A senior’s nightmare under a guardian’s ‘care’
Next post GM cuts Chevy Blazer EV price as sales restart following software issues